Exchange: NASDAQ·Updated 04:04 PM EDT
COLL logo

COLLCollegium Pharmaceutical Inc

$35.87
$0.33
(0.91%)
Today
Closed $35.87
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$1.17B
Vol404,942.00
News
all
press releases
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Zacks
News Placeholder
More News
News Placeholder
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.
Zacks
News Placeholder
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
News Placeholder
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
News Placeholder
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday
Collegium Pharmaceutical (NASDAQ:COLL) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat
News Placeholder
Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Collegium Pharmaceutical in a research note issued on...
MarketBeat
News Placeholder
Equities Analysts Offer Predictions for COLL Q2 Earnings
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Collegium Pharmaceutical in a...
MarketBeat
News Placeholder
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.